These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19622291)

  • 1. [Antitumor effect of CpG oligonucleotides on human neuroblastoma xenografts in nude mice].
    Yao QH; Tang YJ; Gao FH; Tang JY
    Ai Zheng; 2009 Apr; 28(4):344-9. PubMed ID: 19622291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin.
    Ishii KJ; Kawakami K; Gursel I; Conover J; Joshi BH; Klinman DM; Puri RK
    Clin Cancer Res; 2003 Dec; 9(17):6516-22. PubMed ID: 14695156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.
    Carpentier AF; Chen L; Maltonti F; Delattre JY
    Cancer Res; 1999 Nov; 59(21):5429-32. PubMed ID: 10554011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligodeoxynucleotide stimulates protective innate immunity against human renal cell carcinoma xenografted in nude mice.
    Zhou PJ; Ma BB; He W; Xu D; Wang XH
    J Immunother; 2011 Sep; 34(7):535-41. PubMed ID: 21760530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
    De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
    Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides.
    van der Most RG; Himbeck R; Aarons S; Carter SJ; Larma I; Robinson C; Currie A; Lake RA
    J Immunother; 2006; 29(2):134-42. PubMed ID: 16531814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
    De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
    J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
    Ballas ZK; Rasmussen WL; Krieg AM
    J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
    Wang J; Zhang W; He A; Zhao W; Cao X
    Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
    Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
    Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ
    J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.
    Brignole C; Marimpietri D; Di Paolo D; Perri P; Morandi F; Pastorino F; Zorzoli A; Pagnan G; Loi M; Caffa I; Erminio G; Haupt R; Gambini C; Pistoia V; Ponzoni M
    Cancer Res; 2010 Dec; 70(23):9816-26. PubMed ID: 20935225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
    Ishii KJ; Gursel I; Gursel M; Klinman DM
    Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.